High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study.
Reports have been published on blood coagulation disturbances by valproate therapy. In the present prospective trial, blood samples were drawn before valproate therapy, after 6 weeks of therapy, after more than 6 weeks and after longer than 6 months of valproate therapy from 23 children newly treated with valproate. Two children developed thrombocytopenia, and six children with initial normal von Willebrand factor showed acquired von Willebrand's disease. Fibrinogen levels dropped below the lower limit in 12 patients and subnormal factor XIII plasma levels were observed in 17% of patients. No patient developed signs of hemorrhage. Eight percent of patients developed valproate-induced thrombocytopenia. Reduction in platelets did not reach statistic significance. Thrombelastography showed a 47% incidence of altered platelet function. We found a statistically significant, positive correlation between clotting time of collagen extrinsic pathway inhibitor and, accordingly, adenosindiphosphate and valproate level. Plasmatic coagulation investigations showed a significant decrease of prothrombin time. Activated partial thromboplastin time measurements also showed significant prolongation with valproate. Activity of von Willebrand factor antigen and von Willebrand factor ristocetin cofactor significantly decreased. Factor XIII activity significantly decreased after valproate therapy for longer than 6 months (17% of children). Fibrinogen was significantly reduced. In the coagulatory system a decrease in the main antiprotease antithrombin III activity was observed. Blood coagulation disturbances are common in patients with valproate, but rarely become clinically symptomatic. Acquired von Willebrand's disease and hypofibrinogenemia may become relevant in patients with surgery or trauma. Particular attention should be paid to factor-XIII deficiency, which is especially seen with valproate therapy.
Koenig
Stephan
S
Department of Pediatrics, Germany, Mannheim University Hospital, University of Heidelberg, Germany. drstkoenig@aol.com
Gerstner
Thorsten
T
Keller
Anja
A
Teich
Martin
M
Longin
Elke
E
Dempfle
Carl-Erik
CE
D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects*; D001792:Blood Platelets / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D005176:Factor XIII / Q000032:analysis; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D008297:Male; D011446:Prospective Studies; D013916:Thrombelastography / Q000379:methods; D013921:Thrombocytopenia / Q000097:blood* / Q000139:chemically induced*; D014635:Valproic Acid / Q000008:administration & dosage / Q000009:adverse effects*; D014842:von Willebrand Diseases / Q000097:blood* / Q000139:chemically induced*; D014841:von Willebrand Factor / Q000032:analysis / Q000276:immunology
D000927:Anticonvulsants; C029417:Von Willebrand antigen; D014841:von Willebrand Factor; D014635:Valproic Acid; D005340:Fibrinogen; D005176:Factor XIII